A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
ROCKET PHARMACEUTICALS, INC.
RCKT
$354M
Mkt Cap
$3.19
-2.74%
ROCKET PHARMACEUTICALS, INC. (RCKT) has a 5-year average return on invested capital (ROIC) of -47.3%. This is below average and may indicate limited pricing power.
ROCKET PHARMACEUTICALS, INC. (RCKT) has a market capitalization of $348M. It is classified as a small-cap stock.
ROCKET PHARMACEUTICALS, INC. (RCKT) does not currently pay a regular dividend.
ROCKET PHARMACEUTICALS, INC. (RCKT) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
ROCKET PHARMACEUTICALS, INC. (RCKT) generated $-190 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
ROCKET PHARMACEUTICALS, INC. (RCKT) has a debt-to-equity ratio of 0.09. This indicates a conservatively financed balance sheet.
ROCKET PHARMACEUTICALS, INC. (RCKT) reported earnings per share (EPS) of $-2.01 in its most recent fiscal year.
We are a fully integrated, late-stage biotechnology company focused on the development, manufacturing, and potential commercialization of genetic therapies for rare and often fatal diseases with high unmet medical need. Our innovative multi-platform approach is designed to create best-in-class gene therapy product candidates aimed at correcting the underlying genetic causes of complex inherited cardiomyopathies and related disorders, with the potential to deliver transformative and durable clinical benefits. Our platform is supported by in-house research and development capabilities and current cGMP manufacturing facilities that enable end-to-end control of clinical production, process development, and scale-up for potential commercialization. Our Strategy We seek to bring hope and relief to patients with devastating, undertreated and rare diseases through the development and commercialization of potentially curative first-in-class gene therapies.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -209M | -223M | -259M | -246M | -222M | -169M |
| EPS | $-1.93 | $-2.01 | $-2.73 | $-2.92 | $-3.26 | $-2.67 |
| Free Cash Flow | -180M | -190M | -216M | -211M | -187M | -129M |
| ROIC | -148.4% | -57.3% | -52.0% | -48.1% | -45.1% | -33.9% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.09 | 0.09 | 0.06 | 0.05 | 0.05 | 0.05 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -216M | -232M | -273M | -260M | -224M | -167M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -88.0% | -60.3% | -54.1% | -50.0% | -47.0% | -35.3% |
| Shares Outstanding | 109M | 111M | 95M | 84M | 68M | 63M |
| Metric | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 6.0M | 15M | 53M | 58M | 105M | 125M | 166M | 186M | 171M | 142M | 138M |
| SG&A | 1.6M | 4.9M | 18M | 18M | 29M | 42M | 59M | 73M | 102M | 87M | 75M |
| EBIT | -7.6M | -20M | -71M | -76M | -134M | -167M | -224M | -260M | -273M | -232M | -216M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -7.6M | -20M | -75M | -77M | -140M | -169M | -222M | -246M | -259M | -223M | -209M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 437K | -317K | 0 | 0 | 0 | 0 | 0 | 0 | 3.2M | 3.2M |
| Returns on Capital | |||||||||||
| ROIC | -51.0% | -163.9% | -59.4% | -28.5% | -33.7% | -33.9% | -45.1% | -48.1% | -52.0% | -57.3% | -148.4% |
| ROE | -63.3% | -163.9% | -71.1% | -30.8% | -34.5% | -35.3% | -47.0% | -50.0% | -54.1% | -60.3% | -88.0% |
| ROA | -6.2% | -26.1% | -54.9% | -24.8% | -29.0% | -31.1% | -42.3% | -43.9% | -47.3% | -52.0% | -73.4% |
| Cash Flow | |||||||||||
| Op. Cash Flow | -5.5M | -16M | -54M | -65M | -75M | -121M | -178M | -195M | -210M | -190M | -180M |
| Free Cash Flow | -5.8M | -17M | -55M | -88M | -95M | -129M | -187M | -211M | -216M | -190M | -180M |
| Owner Earnings | -5.8M | -18M | -68M | -78M | -94M | -154M | -213M | -239M | -261M | -236M | -223M |
| CapEx | 335K | 760K | 1.5M | 23M | 21M | 7.6M | 8.4M | 16M | 5.9M | 440K | 169K |
| Maint. CapEx | 67K | 270K | 330K | 426K | 1.1M | 3.2M | 3.9M | 4.9M | 7.2M | 8.9M | 8.0M |
| Growth CapEx | 268K | 490K | 1.1M | 23M | 19M | 4.4M | 4.5M | 12M | 0 | 0 | 0 |
| D&A | 67K | 270K | 330K | 426K | 1.1M | 3.2M | 3.9M | 4.9M | 7.2M | 8.9M | 8.0M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 72K | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | 0.1% | N/A | 0.0% | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 274K | 1.3M | 14M | 13M | 19M | 29M | 31M | 39M | 44M | 37M | 35M |
| Debt Repayment | 0 | 0 | 0 | 0 | 237K | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||||
| Net Debt | N/A | -18M | -164M | -257M | -461M | -366M | -334M | -348M | -347M | -164M | -123M |
| Cash & Equiv. | 30M | 18M | 111M | 185M | 297M | 233M | 141M | 56M | 164M | 78M | 144M |
| Long-Term Debt | N/A | 0 | 41M | 0 | 19M | 19M | 19M | 19M | 19M | 19M | 19M |
| Debt/Equity | 6.75 | 0.00 | 0.21 | 0.15 | 0.04 | 0.05 | 0.05 | 0.05 | 0.06 | 0.09 | 0.09 |
| Interest Coverage | N/A | N/A | -11.8 | -12.8 | -19.3 | -56.2 | -120.5 | -138.5 | -144.9 | -122.6 | -122.6 |
| Equity | 8.4M | 16M | 194M | 307M | 504M | 455M | 490M | 493M | 463M | 277M | 238M |
| Total Assets | 130M | 20M | 251M | 372M | 591M | 497M | 552M | 566M | 528M | 330M | 285M |
| Total Liabilities | 56M | 4.6M | 57M | 65M | 87M | 42M | 62M | 74M | 64M | 53M | 47M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | 0 | 26M | 25M | 25M | 25M | 25M |
| Retained Earnings | -239M | -31M | -106M | -183M | -323M | -492M | -714M | -959M | -1.2B | -1.4B | -1.5B |
| Working Capital | 121M | 14M | 194M | 289M | 455M | 370M | 325M | 330M | 337M | 163M | 125M |
| Current Assets | 128M | 19M | 209M | 308M | 487M | 392M | 364M | 378M | 378M | 193M | 150M |
| Current Liabilities | 7.0M | 4.5M | 15M | 18M | 33M | 22M | 39M | 49M | 41M | 30M | 24M |
| Per Share Data | |||||||||||
| EPS | -1.11 | -2.88 | -1.89 | -1.58 | -2.52 | -2.67 | -3.26 | -2.92 | -2.73 | -2.01 | -1.93 |
| Owner EPS | -0.86 | -2.58 | -1.72 | -1.60 | -1.70 | -2.43 | -3.13 | -2.84 | -2.75 | -2.13 | -2.04 |
| Book Value | 1.23 | 2.28 | 4.92 | 6.28 | 9.08 | 7.18 | 7.20 | 5.86 | 4.89 | 2.50 | 2.18 |
| Cash Flow/Share | -0.81 | -2.35 | -1.36 | -1.32 | -1.35 | -1.91 | -2.62 | -2.32 | -2.21 | -1.71 | -1.85 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 6.8M | 6.8M | 39.4M | 48.9M | 55.4M | 63.3M | 68.1M | 84.1M | 94.8M | 111.0M | 109.1M |
| Valuation | |||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -1.7 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 5.3 | 30.9 | 3.0 | 3.8 | 6.2 | 3.2 | 2.5 | 5.3 | 2.4 | 1.4 | 1.5 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | -13.3% | -3.5% | -9.6% | -7.5% | -3.1% | -8.8% | -15.1% | -8.1% | -19.4% | -49.3% | -51.6% |
| Market Cap | 44M | 480M | 574M | 1.2B | 3.1B | 1.5B | 1.2B | 2.6B | 1.1B | 386M | 348M |
| Avg. Price | 31.52 | 7.37 | 18.35 | 15.51 | 24.42 | 40.78 | 15.89 | 19.96 | 21.75 | 5.39 | 3.19 |
| Year-End Price | 25.80 | 10.64 | 14.55 | 24.06 | 56.32 | 22.99 | 18.13 | 30.90 | 11.75 | 3.48 | 3.19 |
ROCKET PHARMACEUTICALS, INC. passes 0 of 9 quality checks, indicating weak fundamentals.
ROCKET PHARMACEUTICALS, INC. (RCKT) has a return on equity (ROE) of -60.3%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 10 years of financial data for ROCKET PHARMACEUTICALS, INC. (RCKT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ROCKET PHARMACEUTICALS, INC. (RCKT) has a book value per share of $2.50, based on its most recent annual SEC filing.